/
LXRX
$2.64+$0.09 (+3.53%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.1B
444M shares
52-week range
$0.80 – $2.67
98% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Price (6 mo)
Loading chart…
Change$-1.95
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $63.2M | $322.1M | $24.0M | $298.0K | $139.0K | $1.2M | $31.1M | $49.8M |
| Cost of revenue | $2.5M | $3.2M | $1.9M | $55.0M | $52.5M | $59.0M | $616.0K | $274.0K |
| Gross profit | $60.7M | $318.8M | $22.1M | −$54.7M | −$52.4M | −$57.8M | $30.5M | $49.5M |
| Gross margin | 96.1% | 99.0% | 92.0% | -18371.8% | -37681.3% | -4798.0% | 98.0% | 99.4% |
| R&D | $100.2M | $91.9M | $153.6M | $55.0M | $52.8M | $58.9M | $84.5M | $61.1M |
| Operating income | −$103.3M | $141.4M | −$47.8M | −$87.1M | −$100.8M | −$171.8M | −$197.1M | −$48.9M |
| EBITDA | −$96.1M | $148.4M | −$41.1M | −$86.7M | −$100.0M | −$169.8M | −$184.3M | −$41.4M |
| Net income | −$120.5M | $130.1M | −$58.6M | −$87.8M | −$101.9M | −$177.1M | −$200.4M | −$50.3M |
| Net margin | -190.7% | 40.4% | -244.1% | -29449.0% | -73341.0% | -14710.9% | -644.8% | -101.1% |
| EPS (diluted) | -1.14 | 1.11 | -0.63 | -0.61 | -0.62 | -0.80 | -0.63 | -0.14 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $38M | $-0.16 | $-0.17–$-0.15 | 3 |
| 2027 | $20M | $-0.21 | $-0.22–$-0.18 | 3 |
| 2028 | $76M | $-0.09 | $-0.16–$0.05 | 4 |
| 2029 | $99M | $-0.03 | $-0.03–$-0.02 | 2 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
www.lexpharma.com- Employees
- 81
- IPO / List date
- Apr 7, 2000
- HQ
- THE WOODLANDS, TX
Held by traders on TradeandTell
No one on the platform currently holds LXRX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,600,500 | $2.5M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2015-05-21 | 1-for-7reverse |
Recent trades on TradeandTell
No one on the platform has traded LXRX yet.
